Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Erin P. Demakos"'
Autor:
Richa Rai, Camille Bigenwald, Jonathan Feld, Stella Melana, Erin P. Demakos, Amir Horowitz, Lewis R. Silverman
Publikováno v:
Blood. 140:11432-11433
Autor:
Shyamala C. Navada, Patrick S. Zbyszewski, Richard C. Woodman, Naveen Pemmaraju, Rosmy B. John, Guillermo Garcia-Manero, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, Steven M. Fruchtman, Maro Ohanian, Yesid Alvarado, Manoj Maniar
Publikováno v:
Leukemia research. 94
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML; n = 1) who were either hypomethylating agent naive (n = 10) or re
Autor:
Shyamala C. Navada, Richa Rai, Stella M. Melana, Erin P. Demakos, Jonathan Feld, Foramben Patel, Lewis R. Silverman, Rosalie Odchimar-Reissig, E. Premkumar Reddy
Publikováno v:
Blood. 138:4325-4325
Background: Myelodysplastic syndrome (MDS) is a clinically heterogenous disease of hematopoietic stem cells (HSC) characterized by ineffective hematopoiesis, uni/multi-lineage dysplasia and a high tendency to transform into acute myeloid leukemia. Ab
Autor:
Shyamala C. Navada, S. Melana, R. Rai, Rosalie Odchimar-Reissig, Lewis B. Silverman, Erin P. Demakos, E.P. Reddy, F. Patel, Jonathan Feld
Publikováno v:
Leukemia Research. 108:106681.26
Autor:
Foramben Patel, Shyamala C. Navada, Stella M. Melana, Rosalie Odchimar-Reissig, E. Premkumar Reddy, Erin P. Demakos, Jonathan Feld, Lewis R. Silverman, Richa Rai
Publikováno v:
Blood. 136:35-36
Background Myelodysplastic Syndrome (MDS) is characterized by ineffective clonal hematopoiesis with peripheral blood cytopenias, leading to death from infection or bleeding. Azacitidine (AZA), a hypomethylating agent (HMA) is the standard of care for
Autor:
Darshanie Sewah, Erin P. Demakos, Douglas Tremblay, Lewis R. Silverman, Shyamala C. Navada, Jonathan Feld, Rosalie Odchimar-Reissig, Saudia Alli
Publikováno v:
Blood
Background: The COVID-19 (SARS-CoV-2) pandemic has affected cancer patients (pts) in a myriad of ways, including diagnostic & treatment delays, scarcity of blood products, and most importantly, higher risks of morbidity and mortality from the viral i
Autor:
Richa Rai, Shyamala C. Navada, Stella M. Melana, Rosalie Odchimar-Reissig, Erin P. Demakos, Lewis R. Silverman, E. Premkumar Reddy
Publikováno v:
Blood. 134:4231-4231
Background: MDS is characterized by ineffective hematopoiesis and multiple cytopenias. Azacitidine (AZA), a hypomethylating agent (HMA), the standard therapy for higher-risk MDS patients (pts), improves hematopoiesis in 50% of MDS pts, with a median
Autor:
Francesca Schieppati, Jonathan Feld, Erin P. Demakos, Lewis R. Silverman, Rosalie Odchimar-Reissig, Shyamala C. Navada
Publikováno v:
Blood. 134:4260-4260
Background: Patients with Myelodysplastic Syndrome (MDS) with cytopenias have limited treatment options to improve blood counts apart from immune-modulatory drugs (IMIDS), hypomethylating agents (HMA), cytokines and transfusional support. Immune dysr
Autor:
Erin P. Demakos, Shyamala C. Navada, Stella M. Melana, Richa Rai, Rosalie Odchimar-Reissig, Miriam Merad, Amir Horowitz, Lewis R. Silverman, Camille Bigenwald
Publikováno v:
Blood. 134:2986-2986
Background: Abnormalities of the immune system and innate immune signaling have been described in patients (pts) with MDS, however the interaction between the MDS tumor cells and the immune compartment is poorly defined. Immune modulatory therapies a
Autor:
Ehab Atallah, S.R. Dakhil, Shyamala C. Navada, Erin P. Demakos, G. Garcia-Manero, Y. Alvarado Valero, R.C. Woodman, S.M. Fruchtman, Manoj Maniar, J.M. Shammo, Elizabeth A. Griffiths, R.B. John, M.N. Ohanian, N. Pemmaraju, M.E. Petrone, S.K. Khaled, M.N. Rajeh, Rosalie Odchimar-Reissig, Patrick S. Zbyszewski, Lewis R. Silverman, D.E. Young
Publikováno v:
HemaSphere. 3:373-374